跳至主要内容
临床试验/IRCT20120415009472N21
IRCT20120415009472N21已完成未知

Effect of Sumac powder on Antioxidant indices and Uric Acid in women with polycystic ovary syndrome

Iran University of Medical Sciences0 个研究点目标入组 88 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
88

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20 years 至 40 years(—)
性别
Female

入选标准

  • •Patients with Polycystic ovary Syndrome based on two criteria of the three diagnostic criteria of the disease based on Rotterdam: 1.Bleeding is reduced or discontinued (as Delay more than 35 days or less than 8 bleeding episodes per year) 2. Clinical symptoms including hirsutism or Ferriman-Gallway (MGF) score above 8, acne and male pattern baldness and biochemical symptoms of increased androgenesis. 3. Polycystic ovary (12 or more of 12 follicles per ovary with a diameter of 2 to 9 mm, or an increase in ovarian volume to more than 310 ml). Patients with age between 20 to 40 years old.
  • •patient's acceptance of taking part in the study.

排除标准

  • •Those who take drugs of anticoagulants and hyperlipidemia
  • •Use Tobacco
  • •Having kidney disease, diabetes, liver disease, cardiovascular disorders, hypothyroidism, inflammatory and rheumatic diseases, hyperprolactinemia, Cushing's syndrome, and congenital adrenal hyperplasia Follow a particular diet in the last three months.
  • •Take medications that affect insulin sensitivity, inflammation, or lipid profile and hormonal profile, including glucocorticoid drugs, ovulation induction drugs, anti-obesity, anti-diabetes, antihypertensive, estrogenic, anti-androgen, over the past 3 months
  • •Unwilling to participate in the study
  • •Use of Nutrition Supplements in the last 2 months
  • •Pregnancy or breastfeeding
  • •Sensitization or allergy to sumac

研究者

相似试验

Effect of Sumac in treatment of polycystic ovary... | 临床试验